CD274 and triple-negative breast carcinoma: Barroso-Sousa et al. 62 demonstrated that PTEN mutations were significantly associated with lower ORR (6% vs 48%), shorter PFS (2.3 months vs 6.1 months) and OS (9.7 months vs 20.5 months) in triple-negative breast cancer patients treated with anti PD-1/PD-L1 therapy.